Phaseline

Targets › PNPLA3

PNPLA3 (1-acylglycerol-3-phosphate O-acyltransferase PNPLA3): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.

Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. (UniProt, Q9NST1)

Open in Phaseline: the race on PNPLA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Regeneron PharmaceuticalsALN-PNP
PNPLA3 inhibitor (reduces Patatin-like phospholipase domain-containing protein 3 expressio
PNPLA3Phase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); Healthy VolunteersAug 2027

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (1) Healthy Volunteers (1)

Modalities

mixed (1)

Companies

Regeneron Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.